6467344
Last Update Posted: 2025-12-02
Recruiting
All Genders accepted | 12 Years + |
15 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
Study to Evaluate ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR)
This study is an open-label, single ascending dose clinical trial in participants who have ABCA4-related retinopathies. This is the first-in-human clinical trial in which ACDN-01 will be evaluated for safety, tolerability, and preliminary efficacy following a single subretinal injection of ACDN-01.
This study is an open-label, single ascending dose clinical trial in participants who have ABCA4-related retinopathies. This is the first-in-human clinical trial in which ACDN-01 will be evaluated for safety, tolerability, and preliminary efficacy following a single subretinal injection of ACDN-01.
Eligibility
Relevant conditions:
Stargardt Disease
Cone Rod Dystrophy
Juvenile Macular Degeneration
Stargardt Disease 1
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the study if you think are close to fitting criteria.
locations
Contact Information
Overall Contact
Associate Director, Clinical Operations
researchtrials@ascidian-tx.com
207-573-0412
Data sourced from ClinicalTrials.gov